NAMS vs RCUS: stock comparison and AI forecast
Newamsterdam Pharma Co N.V. (NAMS) and Arcus Biosciences, Inc. (RCUS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NAMS Newamsterdam Pharma Co N.V.
- Market Cap
- $2.26B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
RCUS Arcus Biosciences, Inc.
- Market Cap
- $2.55B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- RCUS is 1.1 times larger than NAMS by market capitalization ($2.55B against $2.26B).
- RCUS turns -453.0% of its revenue into net income, against -924.0% for NAMS.
- RCUS carries 1.28 times debt per unit of equity, against 0.09 times for NAMS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NAMS | RCUS |
|---|---|---|
| Market Cap | $2.26B | $2.55B |
| P/B Ratio | 3.58x | 7.12x |
| EPS | $-1.25 | $-3.62 |
| Book Value/Share | $5.28 | $2.48 |
| Revenue/Share | $0.19 | $0.69 |
| FCF/Share | $-1.26 | $-3.23 |
Profitability & Margins
| Metric | NAMS | RCUS |
|---|---|---|
| ROE | -32.5% | -126.5% |
| ROA | -29.8% | -55.4% |
| ROIC | -37.0% | -76.7% |
| Operating Margin | -1052.8% | -475.0% |
| Net Margin | -924.0% | -453.0% |
| EBT Margin | -918.6% | -453.0% |
| Tax Rate | – | 0.0% |
Financial Health
| Metric | NAMS | RCUS |
|---|---|---|
| Current Ratio | 11.76x | 3.34x |
| D/E Ratio | 0.09x | 1.28x |
| Financial Leverage | 1.09x | 2.28x |
| Interest Coverage | – | -43.7x |
| Working Capital | $615M | $465M |
Cash Flow
| Metric | NAMS | RCUS |
|---|---|---|
| Operating Cash Flow | -$150M | -$465M |
| Free Cash Flow | -$151M | -$466M |
| Capital Spending | -$400K | -$1M |
| FCF/Sales | -680.4% | -466.0% |
| CapEx/Sales | 1.8% | 1.0% |
Operational Efficiency
| Metric | NAMS | RCUS |
|---|---|---|
| Asset Turnover | 0.03x | 0.12x |
| Fixed Assets Turnover | 40.0x | 3.0x |
Income Statement
| Metric | NAMS | RCUS |
|---|---|---|
| Total Revenue | $22M | $100M |
| Operating Income | -$233M | -$475M |
| Net Income | -$205M | -$453M |
| R&D Expense | $158M | $473M |
| SG&A Expense | $102M | – |
Dividend & Shareholder Information
| Metric | NAMS | RCUS |
|---|---|---|
| Shares Outstanding | 120M | 144M |
NAMS vs RCUS: stock comparison and AI forecast
Which is bigger, NAMS or RCUS?
RCUS is 1.1 times larger than NAMS by market capitalization ($2.55B against $2.26B).
Which one does Intratio's AI model rank higher, NAMS or RCUS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.